Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma.
作者信息
Cliff Edward R Scheffer, Hilal Talal, Kesselheim Aaron S
机构信息
Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
出版信息
Nat Rev Clin Oncol. 2024 Jan;21(1):1-2. doi: 10.1038/s41571-023-00821-7.
PMID:37735523
Abstract
摘要
Zotero 插件